Zymeworks Inc
Zymeworks Inc logo
ZYME

Zymeworks Inc (ZYME)

$7.620.53%

Market is closed
– opens on 8 PM, 06 Dec 2022
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$7.32
Day's Range
$7.72
$4.11
52-Week Range
$19.08
1 month return4.15%
3 month return60.08%
1 year return58.18%
5 year return76.22%

Company Information

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks' suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks' lead clinical candidate, zanidatamab (ZW25), is a novel Azymetric™ bispecific antibody which has been granted Breakthrough Therapy designation by the FDA and is currently enrolling in a pivotal clinical trial for refractory HER2-amplified biliary tract cancer (HERIZON-BTC-01) as well as several Phase 2 clinical trials for HER2-expressing gastroesophageal and breast cancers. Zymeworks' second clinical candidate, ZW49, is a novel bispecific HER2-targeting antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks' proprietary ZymeLink™ linker and cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies.
OrganizationZymeworks Inc
Employees286
CEOMr. Neil A. Klompas C.A., CPA, CA, CPA
IndustryHealth Technology

Analyst Recommendation

based on 12 analysts ratings

Buy
66%
Buy
33%
Hold
0%
Sell

Based on 12 Wall street analysts offering stock ratings for Zymeworks Inc(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 61.55%

Current

$7.62

Target

$12.31

Recommendation Trend

Based on 12 analyst

Current1M Ago3M Ago
Buy
8
14
14
Hold
4
4
4
Sell
0
0
0
Consensus
BUY
BUY
BUY

Highlights

Market Capitalization
459.6M
Book Value
$2.91
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-4.97
PEG Ratio
0.0
Wall Street Target Price
12.31

Valuation

Trailing PE0.0
Forward PE0.0
Price/Book (mrq)
2.1
Enterprise Value
257.8M
Enterprise Value/Revenue
8.15
Enterprise Value/Ebitda
-1.13

Technicals

Beta
1.11
50 Day MA
6.78
200 Day MA
6.36

Institutional Holdings

Armistice Capital, LLC

9.38%

Redmile Group, LLC

9.35%

Eventide Asset Management, LLC

8.72%

Morgan Stanley - Brokerage Accounts

8.52%

Perceptive Advisors LLC

7.13%

Camber Capital Management LLC

4.64%

Discover more

Frequently Asked Questions

What is Zymeworks Inc share price today?

Can Indians buy Zymeworks Inc shares?

How can I buy Zymeworks Inc shares from India?

Can Fractional shares of Zymeworks Inc be purchased?

What are the documents required to start investing in Zymeworks Inc stocks?

What are today’s High and Low prices of Zymeworks Inc?

What are today’s traded volumes of Zymeworks Inc?

What is today’s market capitalisation of Zymeworks Inc?

What is the 52 Week High and Low Range of Zymeworks Inc?

How much percentage Zymeworks Inc is down from its 52 Week High?

How much percentage Zymeworks Inc is up from its 52 Week low?

What are the historical returns of Zymeworks Inc?

Who is the Chief Executive Officer (CEO) of Zymeworks Inc?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*